Amicus Therapeutics Announces Close of Patient Recruitment in First Phase 3 Study of Amigal for Fabry Disease

by Eddie Staley, Benzinga Editor
October 19, 2011 7:31 AM | 20 seconds read | Make a Comment
Loading...
Loading...
Amicus Therapeutics
FOLD
today announced that patient recruitment has closed in the first Phase 3 global registration study (Study 011) of Amigal™ (migalastat HCl) for Fabry disease. Participating sites have stopped screening new patients, and Amicus and its collaborator GlaxoSmithKline
GSK
continue to anticipate full enrollment this quarter upon initial dosing of the last patient.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!